There are probably fewer than a dozen specialist Gaucher's disease treatment centers in the whole of Europe, and so it seems curious at first that Oxford GlycoSciences PLC (OGS) would need a European partner, Switzerland's Actelion Pharmaceuticals Ltd., for help in marketing oral miglustat (Zavesca, formerly known as Vevesca), its treatment for the lysosomal storage disorder [See Deal].
But Actelion's experience marketing bosentan (Tracleer) worldwide for pulmonary arterial hypertension, and its expertise and established infrastructure in post-approval patient monitoring were what sealed the five-year deal, say executives from...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?